Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/07—Retinol compounds, e.g. vitamin A
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• This invention is drawn to a method of treating hepatitis comprising
• the amount of retinoid such as all- trans retinoic acid.
• the retinoid such as all- trans retinoic acid.
• hepatitis form of hepatitis is viral hepatitis caused by infection with A, B, C, D, E, and G
• Hepatitis is an inflammatory liver disease. It is associated with loss of
• liver may become enlarged and jaundice may be present. Both chronic and acute
• hepatitis is known.
• the acute form subsides, generally after about
• liver disease such as cirrhosis or hepatocellular carcinoma.
• Type A was previously termed infectious
• Type B was previously termed serum hepatitis
• Type C was non-
• Type D was delta hepatitis.
• viruses have been known to exhibit hepatitis as a secondary effect. These viruses include Cytomegalovirus, Epstein-Barr virus, as well as Yellow Fever.
• Hepatitis is also a secondary effect of certain parasites and bacteria infections.
• Non-viral hepatitis is also associated with autoimmune diseases, Wilson's
• hemochromatosis and those diseases of toxic origin such as drug,
• Hepatitis B and C were not drawn.
• Hepatitis C was not drawn.
• non-A non-B hepatitis
• RNA virus of the type described as "Flavivirus” is the cause of Hepatitis C. This
• RNA virus has been described as a 40-50 nanometer linear single-strand RNA
• lipid envelope (ribonucleic acid) virus with a lipid envelope.
• the lipid envelope In native state, the lipid envelope is
• Hepatitis B is caused by a double
• stranded DNA virus of the type known as Hepadnavirus . It is a 42 nm particle
• enterovirus is classified as a genus of the
• Picornaviridae This genus is generally divided into five major groups.
• Enteroviruses are characterized by a high degree of genetic diversity at the VP1
• This invention comprises a method of treating hepatitis comprising
• a ⁇ - trans retinoic acid (inter alia, liposomal all- trans retinoic acid) of at least about 10mg at least about every other day.
• retinoic acid are variously at least about 10 mg/m 2 , at least about 15 mg/m 2 , at
• This method is particularly useful in hepatitis
• viral hepatitis including hepatitis A, B, C, D, E, or G.
• This invention also comprises a method of treating hepatitis comprising
• this includes retinoid in liposomal
• This invention yet further comprises a method of treating enteroviral
• this includes retinoid in liposomal form, and further in
• therapeutically effective amount optionally at least about every other day.
• group consisting of (i) poliovirus, (ii) group A coxsackievirus, (iii) group B
• Echovirus 3 4, 6, 7, 9 or 1 1
• chronic viral disease in a subject comprising administering to said subject a
• retinoid is at least about 50mg at least about every other day.
• ATRA refers to a ⁇ -trans retinoic acid, a retinoid. Retinoids in general
• retinoids include trans-retinoic acid and all- trat?s-retinol.
• Other retinoids are retinoic acid
• retinol retinol, retinyl acetate, retinaldehyde, all-trans-retinoic acid, and 13-cis-retinoic
• Non-liposomal retinoids often suitable for oral administration, are referred to
• Liposomal ATRA or retinoid shall be broadly understood to encompass
• lipids are generally spherical structures comprising lipids, fatty acids, lipid bilayer type
• liposomes are completely closed lipid bilayer membranes containing an entrapped
• Liposomes may be unilamellar vesicles (possessing a single
• bilayer membrane or multilamellar vesicles (onion-like structures characterized
• the bilayer is composed of two lipid monolayers having a hydrophobic
• bilayer is such that the hydrophobic (nonpolar) "tails" of the lipid monolayers
• Liposomes are vesicles composed of one or more concentric phospholipid
• liposome and liposomal.
• liposome By way of example of such nonliposomal lipid
• L-ATRA liposomal-ATRA
• retinoids as
• liposomal- ATRA or "-retinoid” shall extend to
• Hepatitis shall be broadly construed in reference to inflammatory liver
• viral hepatitis are also contemplated within this invention.
• Therapeutically effective amount as to a drug dosage shall mean that
• a therapeutically effective amount shall include
• effective amount is about 50 to about 150 mg administered at least about every
• a therapeutically effective amount shall mean about
• ATRA is about 50 to about 150 mg administered at least about every other day.
• anti-cancer activities retinoids, including ATRA act to reduce the viral load in
• hepatitis patients with particular reference to hepatitis B and C.
• hepatitis B and C hepatitis B and C.
• liposomal retinoid such as L-ATRA is effective.
• C hepatic enzymes (SPGT and SGOT), bilirubin, and alkaline phosphatase).
• a 34 year old female is diagnosed by serological tests as positive for
• a 54 year old male is diagnosed by serological tests as positive for
• hepatitis A hepatic enzymes
• APL started to receive L-ATRA (ATRAGEN ® ) QOD at 90 mg/m 2 .
• ATRAGEN ® L-ATRA
• liver function test liver function test
• HCR hematologic complete remission
• compositions of this invention possess valuable pharmacological properties
• enteroviruses and hepatitis associated viruses in human and veterinary medicine.
• compositions are particularly useful in treating hepatitis A, B, C, D, E,
• compositions can be used in ]n vitro methodologies,
• the present invention can be employed in admixture with carriers, excipients and
• compositions of this invention are generally administered to animals,
• mammals including but not limited to mammals such as livestock, household pets,
• injectable particularly suitable are injectable.
• sterile for parenteral application, particularly suitable are injectable.
• solutions preferably oily or aqueous solutions, as well as suspensions,
• emulsions or implants, including suppositories.
• Ampules are convenient unit
• liquids drops, suppositories, or capsules.
• a syrup, elixir, or the like can be used
• compositions of this invention can be any suitable pharmacologically active compositions of this invention.
• carrier substances suitable for parenteral e.g., enteral (e.g., oral or inhalation) or
• Suitable pharmaceutically acceptable carriers include but are not limited to
• compositions can be any suitable pharmaceutical preparations.
• the pharmaceutical preparations can be any suitable pharmaceutical preparations.
• auxiliary agents e.g. They can also be
• antiviral drugs such as alpha interferon, ribavirin, amantadine,
• ganciclovir dideoxycytosine, dideoxyinosine
• rimantadine stavudine, famciclovir, and trifluridine.
• dosage forms include
• injectable, sterile are particularly suitable are injectable, sterile
• solutions preferably suspensions.
• Ampules are convenient unit dosages.
• Sustained or directed release compositions can be formulated, e.g.,
• degradable coatings e.g., by microencapsulation, multiple coatings, etc. It is
• compositions of this invention are dispensed in unit dosage
• liposomal ATRA of from 1 5 to 300 or more mg/m 2 and
• compositions in a specific case will vary according to the specific compositions

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Virology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Molecular Biology (AREA)
• Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Gastroenterology & Hepatology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=23012660

Family Applications (1)

Country Status (4)

Cited By (4)

Citations (3)

Family Cites Families (3)

• 2002
  • 2002-01-31 CA CA002437168A patent/CA2437168A1/en not_active Abandoned
  • 2002-01-31 JP JP2002565582A patent/JP2004522770A/ja not_active Withdrawn
  • 2002-01-31 EP EP02707670A patent/EP1363611A4/de not_active Withdrawn
  • 2002-01-31 WO PCT/US2002/002996 patent/WO2002066022A1/en not_active Application Discontinuation

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events